Serum haloperidol concentration and clinical response in schizophrenia.
Serum haloperidol concentration and clinical response in schizophrenia.
复制标题
精神分裂症的血清氟哌啶醇浓度和临床反应。
DOI：
10.1093/schbul/14.2.283
复制
发表时间：
1988
影响因子：
6.6
通讯作者：
R. Wyatt
中科院分区：
文献类型：
--
作者：
D. G. Kirch;L. Bigelow;E. Korpi;R. Wagner;S. Zalcman;R. Wyatt
先前的研究已经报道了治疗窗口（即，临床反应和药物水平之间的曲线关系）测定血清或血浆中的氟哌啶醇浓度。作者用固定剂量的氟哌啶醇（0.4 mg/kg/d）治疗了30例急性失代偿期精神分裂症住院患者。6周后，临床改善与血清氟哌啶醇浓度之间无统计学显著相关性。血清浓度为5-15 ng/ml的15例受试者与浓度高于15 ng/ml的15例受试者相比，临床改善无差异。这些数据与治疗平台期一致，而不是窗口期，表明在大多数情况下，精神分裂症患者使用大于约30 mg/天的氟哌啶醇剂量没有临床优势。
Previous studies have reported a therapeutic window (i.e., a curvilinear relationship between clinical response and drug level) for haloperidol concentrations in serum or plasma. The authors treated 30 acutely decompensated schizophrenic inpatients with a fixed dose of haloperidol (.4 mg/kg/day). After 6 weeks there was no statistically significant correlation between clinical improvement and serum haloperidol concentration. Fifteen subjects with serum concentrations of 5-15 ng/ml did not differ in clinical improvement compared with 15 subjects who had concentrations above 15 ng/ml. These data are consistent with a therapeutic plateau, rather than a window, and suggest that in most cases there is no clinical advantage to the use of haloperidol doses greater than approximately 30 mg/day in schizophrenic patients.
血浆/红细胞氟哌啶醇比率和急性精神病症状的改善。
DOI：
--
发表时间：
1984
期刊：
The Journal of clinical psychiatry
影响因子：
--
作者：
Neborsky,RJ;Janowsky,DS;Perel,JM;Munson,E;Depry,D
通讯作者：
Depry,D
血清效应混淆了抗精神病药物放射受体测定。
影响因子：
6.1
作者：
Mailman,RB;DeHaven,DL;Halpern,EA;Lewis,MH
通讯作者：
Lewis,MH